Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Zevorcabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
ChiCTR2600126237Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Jun 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zevorcabtagene autoleucel in multiple myeloma (MM), sponsored by Ruijin Hospital. Primary endpoints: Safety profiles (CRS, ICANS, other adverse events), Overall survival (OS) and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
zevorcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2600126237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126237.